A practical reference on Lipodystrophy: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
112—single emergency 101—the Fire Service and the Ministry of Emergency Situations 102—the police 103—ambulance 104—gas emergency Moscow's Emergency Medical Service (EMS) is the second most efficient among the world's megacities, according to the consultancy PwC in a study called "Analysis of EMS Efficiency in Megacities of the World".
Thallium is the heaviest stable element in group 13 of the periodic table. At the bottom of the periodic table, the inert-pair effect is quite strong, because of the relativistic stabilisation of the 6s orbital and the decreasing bond energy as the atoms increase in size so that the amount of energy released in forming two more bonds is not worth the high ionisation energies of the 6s electrons. It displays the +1 oxidation state that all the known alkali metals display, and thallium compounds with thallium in its +1 oxidation state closely resemble the corresponding potassium or silver compounds stoichiometrically due to the similar ionic radii of the Tl+ (164 pm), K+ (152 pm) and Ag+ (129 pm) ions. It was sometimes considered an alkali metal in continental Europe (but not in England) in the years immediately following its discovery, and was placed just after caesium as the sixth alkali metal in Dmitri Mendeleev's 1869 periodic table and Julius Lothar Meyer's 1868 periodic table. Mendeleev's 1871 periodic table and Meyer's 1870 periodic table put thallium in its current position in the boron group and left the space below caesium blank. However, thallium also displays the oxidation state +3, which no known alkali metal displays (although ununennium, the undiscovered seventh alkali metal, is predicted to possibly display the +3 oxidation state). The sixth alkali metal is now considered to be francium.
It was once widely promoted that excessive absinthe drinking caused effects that were discernible from those associated with alcoholism, a belief that led to the coining of the term absinthism. One of the first vilifications of absinthe followed an 1864 experiment in which Magnan simultaneously exposed one guinea pig to large doses of pure wormwood vapour, and another to alcohol vapours. The guinea pig exposed to wormwood vapour experienced convulsive seizures, while the animal exposed to alcohol did not. Magnan would later blame the naturally occurring (in wormwood) chemical thujone for these effects. Thujone, once widely believed to be an active chemical in absinthe, is a GABA antagonist, and while it can produce muscle spasms in large doses, there is no direct evidence to suggest it causes hallucinations. Past reports estimated thujone concentrations in absinthe as being up to 260 mg/kg. More recently, published scientific analyses of samples of various original absinthes have disproved previous estimates, and demonstrated that only a trace of the thujone present in wormwood actually makes it into a properly distilled absinthe when historical methods and materials are employed to create the spirit. As such, most traditionally crafted absinthes, both vintage and modern, fall within the current EU standards. Tests conducted on mice to study toxicity showed an oral LD50 of about 45 mg thujone per kg of body weight, which represents far more absinthe than could be realistically consumed.
== Function == Humanin has several cytoprotective effects. Humanin and related peptides have antiinflammatory, immunomodulatory and neuroprotective effects and are of interest in the treatment of cardiovascular diseases such as atherosclerosis and heart failure, and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Sources: en.wikipedia.org
The provisions of the Codex Alimentarius are that any "first generation" product must be labeled "irradiated" as any product derived directly from an irradiated raw material; for ingredients the provision is that even the last molecule of an irradiated ingredient must be listed with the ingredients even in cases where the unirradiated ingredient does not appear on the label. The RADURA-logo is optional; several countries use a graphical version that differs from the Codex-version. The suggested rules for labeling is published at CODEX-STAN – 1 (2005), and includes the usage of the Radura symbol for all products that contain irradiated foods. The Radura symbol is not a designator of quality. The amount of pathogens remaining is based upon dose and the original content and the dose applied can vary on a product by product basis. The European Union follows the Codex's provision to label irradiated ingredients down to the last molecule of irradiated food. The European Union does not provide for the use of the Radura logo and relies exclusively on labeling by the appropriate phrases in the respective languages of the Member States. The European Union enforces its irradiation labeling laws by requiring its member countries to perform tests on a cross section of food items in the market-place and to report to the European Commission. The results are published annually on EUR-Lex. The US defines irradiated foods as foods in which the irradiation causes a material change in the food, or a material change in the consequences that may result from the use of the food.
== Etymology == The word pepper derives from Old English pipor, Latin piper, and Greek πέπερι. The Greek likely derives from Sanskrit. In the 16th century, people began using pepper to also mean the New World chilli pepper (genus Capsicum), which is not closely related.
=== Proton nuclear magnetic resonance (NMR) === Also in chemistry, the term proton NMR refers to the observation of hydrogen-1 nuclei in (mostly organic) molecules by nuclear magnetic resonance. This method uses the quantized spin magnetic moment of the proton, which is due to its angular momentum (or spin), which in turn has a magnitude of one-half the reduced Planck constant. (
Scott Long, writing in The Guardian on 31 March, criticised Galloway's claim that "homosexuals are not executed in Iran, just rapists," pointing out that current law in the country stipulates that "Penetrative sex acts between men can bring death on the first conviction." Gay rights activist Peter Tatchell, writing in The Guardian on 26 March, wrote that Galloway's "passionate opposition to a war against Iran, which I share, seems to have clouded his judgement" and "his claim that lesbian and gay people are not at risk of execution in Iran is refuted by every reputable human rights organisation, including Amnesty International, Human Rights Watch, the International Gay and Lesbian Human Rights Commission and the International Lesbian and Gay Association". In August 2010, on his Press TV programme The Real Deal, Galloway interviewed President Mahmoud Ahmadinejad, following Galloway's participation in a conference for expatriate Iranians whose expenses were paid by Iran's government. He discussed Sakineh Mohammadi Ashtiani, an Iranian woman convicted of adultery and sentenced to stoning, which he described as "the so-called stoning case". Galloway said of Ashtiani's sentence: "Every so often an issue comes along which is seized upon by the enemies of Iran and it becomes a heavy problem and magnified ...". According to Martin Fletcher in The Times, Ahmadinejad gave "mendacious answers" which "went unchallenged by his obsequious interlocutor".
NAD(P)H dehydrogenase [quinone] 1 is an enzyme that in humans is encoded by the NQO1 gene. This protein-coding gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a 2-electron reductase (enzyme). This FAD-binding protein forms homodimers and performs two-electron reduction of quinones to hydroquinones and of other redox dyes. It has a preference for short-chain acceptor quinones, such as ubiquinone, benzoquinone, juglone and duroquinone. This gene has an important paralog NQO2. This protein is located in the cytosol. NQO1 enzyme expression can be induced by dioxin and inhibited by dicoumarol.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.